The document provides an overview of various faculty members at a College of Pharmacy, detailing their research interests, publications, and professional roles, particularly in clinical pharmacy, pharmacology, medicinal chemistry, and pharmacy education. Key areas of focus include optimization of medication management, development of new drug therapies, toxicology, and the creation of innovative educational practices in pharmacy. Notable accomplishments include the establishment of animal models for research, advancements in drug discovery using natural products, and the application of machine learning in clinical settings.

1. Research
College of Pharmacy

3. 陳香吟 教授 Prof. Shawn Hsiang-Yin Chen, M.S., Pharm.D.
Clinical Pharmacy and Medication Management
Optimization the medication use and pharmacy service in clinical practice
Representative Publications
 Development and evaluation of new technologies to support pharmacy practice
Using machine learning algorithms to evaluate cloud-based medication records record
Dr. Chen completed her clinical research and practice training at the University of Iowa. Dr. Chen has been the current Associated
Dean for education and global engagement at the College of Pharmacy from 2018 until now. She has been the pharmacy director at
TMU-Wanfang Medical Center for 12 years, establishing complementary pharmacy care models. Research in Dr. Chen’s laboratory is
focused on optimizing medication use in clinical settings. Applying the skills of pharmacogenomics, pharmacovigilance, and
bioinformatics, she published many articles on cisplatin-induced nephrotoxicity, tuberculosis agents-induced hepatic injury,
medication error prevention, formulary management, cost containment, medication reconciliation, pharmacy informatics, opioid use
and clinical pharmacy service (IV-to-PO service, anticoagulation, and antibiotics stewardship) for documenting the value of clinical
pharmacy service. Dr. Chen is the founding President of the American College of Clinical Pharmacy (ACCP) Taiwan Chapter.
1. Lai NH, Shen WC, Lee CN, Chang JC, Hsu MC, Kuo LN, Yu MC, Chen HY*. Comparison of the
Predictive Outcomes for Anti-Tuberculosis Drug-Induced Hepatotoxicity by Different Machine
Learning Techniques. Computer Methods and Programs in Biomedicine. 2020; 188:105307.
2. Sarasmita MA, Larasanty LP, Kuo LN, Cheng KJ, Chen HY*. Computer-Based Interactive Narrative
and Serious Game for Children with Asthma: Development and Content Validity Analysis.
Journal of Medical Internet Research. 2021; 23 (9) e28796: 1-15.
3. Leong CM, Lee TI, Chien YM, Kuo LN, Kuo YF, Chen HY*. Social Media–Delivered Patient
Education to Enhance Self-management and Attitudes of Patients with Type 2 Diabetes During
the COVID-19 Pandemic: Randomized Controlled Trial. Journal of Medical Internet Research.
2022;24(3):e31449: 1-14.
4. Huang SH, Chu CY, Hsu YC, Wang SY, Kuo LN, Bai KJ, Yu MC, Chang JH, Liu EH, Chen HY*. How
Platinum-Induced Nephrotoxicity occurs? Machine Learning Prediction in Non-small Cell Lung
Cancer Patients. Computer Methods and Programs in Biomedicine. 2022; 221:e106839:1-11
(SCI)
5. Lin YT, Chu CY, Hung KS, Lu CH, Bednarczyk EM, Chen HY*. Can Machine Learning Predict
Pharmacotherapy Outcomes? An Application Study in Osteoporosis. Computer Methods and
Programs in Biomedicine. 2022; 225: e107028:1-9. (SCI)
6. Lu YT, Chao HJ, Chiang YC, Chen HY*. Explainable Machine Learning Techniques to Predict
Amiodarone-Induced Thyroid Dysfunction Risk: Multicenter, Retrospective Study with External
Validation. Journal of Medical Internet Research. 2023;25(3): e43734: 1-17.
7. Wu YT, Lu YT, Chu CY, Chao HJ, Kuo LN, Cheng KJ, Chen HY*. Is use of a long-term proton
pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in
Taiwan? A neglected clinical drug-drug Interaction. Family Practice, 2023, XX, 1–8

4. 鄭幼文 教授 Professor, Yu-Wen Cheng
Ophthalmic Pharmacology, Toxicology, Risk Assessment
1. Drugs Development of Retinopathy and Age-Relative Macular
Degeneration Diseases.
2. Toxicity testing for food, drugs, and cosmetics.
1. Fitriana I, Wu GH, Hsu TJ, Chan YJ, Li CH, Lee CC, Hsiao G, Cheng YW*, (2023). Activation of aryl hydrocarbon receptor by azatyrosine-
phenylbutyric hydroxamide inhibits progression of diabetic retinopathy mice. Biochemical Pharmacology.(1):1-13. (IF:5.8; 14.0 %) SCI
2. Chan YJ, Hsiao G, Wan WH, Tsai CH, Kang JJ, Lee YC, Fang TC, Cheng YW*, Li CH* (2023). Blue light exposure collapses the inner
blood-retinal barrier by accelerating endothelial CLDN5 degradation through the disturbance of GNAZ and the activation of ADAM17. Fluids
and Barriers of the CNS. (20):1-20. (IF:6.961; 16.4%) SCI
3. Lin FL, Cheng YW*, Chen LH, Ho JD,, Yen JL,, Wang MH, Lee TH*, Hsiao G* (2023).Retinal protection by fungal product theissenolactone
B in a sodium iodate-induced AMD model through targeting retinal pigment epithelial matrix metalloproteinase-9 and microglia activity.
Biomedicine & Pharmacotherapy.(158):114138-114148. (IF:7.419; 9.3%) SCI
4. Chan YJ, Liao PL, Tsai CH, Cheng YW, Lin FL, Ho JD, Chen CY, Li CH* (2021) Titanium dioxide nanoparticles impair thei nner blood-
retinal barrier and retinalelectrophysiology through rapid ADAM17activation and claudin-5 degradation. Particle and Fibre Toxicology.(18):1-
16. (IF:9.4; 3.2%) SCI
5. Hsu, TJ, Nepali, K, Tsai, CH, Lin FL, Hsiao, G, Lai, MJ*, Cheng YW* (2021) The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-
Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production. Molecules. (26):4359--4378.
(IF:4.411; 35.4%) SCI
Our laboratory has established a chronic animal model for a spectrum of
ophthalmic diseases, including blue light-induced dry macular degeneration,
diabetic retinopathy, glaucoma, retinitis pigmentosa, and immune-related
retinal diseases, and is actively engaged in developing a variety of
pharmacological treatments ranging from small molecules and
nanomedicine to protein drugs and herbal medicine extracts
Research Topic
Representative Publications
Establishment of Animal Models in Ocular Disease for Advancement of Drug Discovery

5. 黃偉展 教授 Prof. Wei-Jan Huang
Medicinal Chemistry and Natural Product Chemistry
Discovery of small molecules with biological activities using rational drug strategy.
Representative Publications
1. Hsu JY, Hsu KC, Sun C, Chou CH, Lin TE, Sung TY, Tseng HJ, Yen SC, Yang CR*, Huang WJ*. Design, synthesis, and
biological evaluation of indolin-2- one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors. Biomed &
Pharmacother. 2023;159:14258. (IF:7.5)
2. Chu JC, Tseng HJ, Lee SB, Hsu KC, Hsin LW, Liang RH, Lin TE, Gao NC, Chen LC, Lu WH, Wang AHJ, Huang WJ*.
Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone
deacetylase inhibitory activities. J Enz Inhib and Med Chem. 2023; 38: 2212326.(IF:5.6).
3. Hsu KC, Chu JC, Tseng HJ, Liu CI, Wang HC, Lin TE, Lee HS, Hsin LW, Wang AHJ, Huang LC*, Huang WJ*. Synthesis and
biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
Eur J Med Chem. 2021; 219: 113419.(IF:6.7)
4. Hsu JY, Sathyan AR, Hsu KC, Chen LC, Yen CC, Tseng HJ, Wu KC, Liu HK*, Huang WJ*. Synthesis of Yakuchinone B-
Inspired Inhibitors against Islet Amyloid Polypeptide Aggregation. J. Nat. Prod. 2021; 84: 1096–1103. (IF5.1)
5. Yen SC, Chen LC, Huang HL, Ngo ST, Wu YW, Lin TE, Sung TY, Lien ST, Tseng HJ, Pan SL, Huang WJ*, Hsu KC*.
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid
Leukemia. J. Nat. Prod. 2021; 84: 1–10. (IF:5.1)
6. Tseng HJ, Lin MH, Shiao YJ, Yang YC, Chu JC, Chen CY, Chen YY, Lin TE, Su CJ, Pan SL, Chen LC, Wang CY, Hsu KC*,
Huang WJ*. Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against
Alzheimer's disease. Eur J Med Chem. 2020; 192:112193. (IF:6.7)
We are interested in developing small molecules against cancers, neurodegenerative diseases and CNS disorders that are characterized
with unmet medical needs. Using rational drug design approach, we have produced several series of novel compounds. One of
resulting series have advanced to the clinical trial and one achievement has been licensed to industry.
 Discovery of small molecules targeting Cancers, Neurodegenerative diseases, and CNS disorders
 Structure optimization using rational drug design and molecular modeling approach
 Natural product-inspired drug development

6. 李慶國 教授 Prof. Ching-Kuo Lee
Plant metabolism and Development of cosmetic ingredients.
Research Topics
Representative Publications
 Discovery and Development of new cosmetic ingredients
 Plant Metabolism and Medicinal Phyto-compounds
 Application of Hyphenated Techniques in Drug Development
1. Liu, T. W.; Hsu, S.J.; Hsieh, Y. S. Y.; Liu, H. K.; Lee, C. K. J. Ethnopharmacology 2024.
in press.
2. Hsiao, S. W.; Kuo, I. C.; Lee, T. H.; Cheng, C. H., Meu, H. C.; Lee, C. K. Arabian J.
Chem. 2023, 16, 105035.
3. Hsu, S. J.; Verpoorte, R.; Lin, S. M.; Lee, C. K. Food Research International 2021, 41,
110170.
The development strategy of Natural product.
Beauty of nature
Research in our laboratory is focused on Development of new
cosmetic ingredients (Whitening, Anti-Aging); understand the
changes in plant metabolites in different environments; investigate
the effect of plant secondary metabolites and rapid analysis of life
body with MS (UHPLC-MS/MS).

8. Representative publications
 Social Aspects of Medication Use
 Innovations in Pharmacy Education
 Patient Medication Experience
 Hospital & Community Pharmacy Practice
1. Wen MJ, Hsu HL, Chang CL, Wang JH, Kuo CN, Hsin YC, Chang EH*. Understanding the medication experience of patients with advanced non-
small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study. PLoS One. 2023 May
30;18(5):e0286333.
2. Huang CY, Hu CJ, Huang LK, Chang EH*. Effects of caregiver counseling on medication persistence and adherence in patients with dementia at a
pharmacist-managed clinic: A pilot study. J Clin Pharm Ther. 2022 Dec;47(12):2074-2082.
3. Chen YW, Huang CY, Chen JH, Hsiao CL, Hong CT, Wu CY, Chang EH*. Living with Parkinson's disease: disease and medication experiences
of patients and caregivers. Int J Qual Stud Health Well-being. 2022 Jan;17(1):2018769.
4. Wu SE, Wen MJ, Chen JH, Shen WC, Chang EH*. A qualitative study on the development of pharmacist-managed clinics in Taiwan. J Clin Pharm
Ther. 2021 Aug;46(4):966-974.
5. Chen PF, Chang EH*, Unni EJ, Hung M. Development of the Chinese Version of Medication Adherence Reasons Scale (ChMAR-Scale). Int J
Environ Res Public Health. 2020 Aug 2;17(15):5578.
6. Lin CW, Chang EH, Clinciu DL, Peng YT, Huang WC, Wu CC, Wu JC, Li YC*. Using modified information delivery to enhance the traditional
pharmacy OSCE program at TMU - a pilot study. Comput Methods Programs Biomed. 2018 May;158:147-152.
Dr. Chang’s research group focuses on pharmacy practice and education. We believe
that practice-based research is important for expanding pharmacist roles and advancing
the pharmacy profession. In particular, we are interested in understanding patient
perceptions of medication use and evaluating interventions to improve patient outcomes.
Our group specializes in qualitative methods and mixed quantitative and qualitative
methods. Recent projects involve cultural competency, medication adherence, and
innovative teaching in pharmacy.
張雅惠 副教授 Associate Prof. Elizabeth H. Chang
Clinical, Social and Administrative Pharmacy

9. 陳美全 教授 Prof. Mei-Chuan Chen
Cancer Pharmacology, Cancer Biology, Signal transduction
Representative Publications
 Pre-clinical Drug Screening and Drug Discovery 臨床前藥物篩選與評估
 Target-identification and mechanism-of-action studies of novel small molecules and herbal medicine
小分子與中草藥藥物作用標的與機轉探討
1. Chang CH, Lin BJ, Chen CH, Nguyen NL, Hsieh TH, Su JH, Chen MC*. Stellettin B Induces Cell Death in Bladder Cancer Via
Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade. Mar Drugs. 2023 Jan 21;21(2):73. (IF: 5.4, 18%)
2. Ojha R, Chen IC, Hsieh CM, Nepali K, Lai RW, Hsu KC, Lin TE, Pan SL, Chen MC*, Liou JP*. Installation of Pargyline, a
LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. J
Med Chem. 2021 Dec 23;64(24):17824-17845. (IF: 7.3, 6.7%)
3. Nguyen NL, Vo TH, Lin YC, Liaw CC, Lu MK, Cheng JJ, Chen MC*, Kuo YH*. Arenarosides A-G, Polyhydroxylated
Oleanane-Type Saponins from Polycarpaea arenaria and their Cytotoxic and Antiangiogenic Activities. J Nat Prod. 2021 Feb
26;84(2):259-267. (IF: 5.1, 13.8%)
4. Wu WC, Liu YM, Liao YH, Hsu KC, Lien ST, Chen IC, Lai MJ, Li YH, Pan SL, Chen MC*, Liou JP*. Fluoropyrimidin-2,4-
dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells. Eur J Med Chem. 2020 Oct
1:203:112540. (IF: 6.7, 11.7%)
5. Ojha R,Nepali K ,Chen CH, Chuang KH, Wu TY, Lin TE, Hsu KC, Chao MW, Lai MJ, Lin MH, Huang HL, Chang CD, Pan SL,
Chen MC*, Liou JP*. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer
in vitro and in vivo. Eur J Med Chem. 2020 Mar 15:190:112086. (IF: 6.7, 11.7%)
We are interested in cell death, autophagy, epigenetic regulation, and DNA damage signaling pathways in cancerous cells. As
tumor cells tend to escape from apoptosis by upregulating survival signalings or loss of tumor suppressor genes, induction of
programmed cell death by novel small molecules or herbal medicine initiates proapoptotic response and leads to anticancer activity.
In order to inhibit cancer cells proliferation and overcome drug resistance, currently we are focusing on antitumor effects and
mechanism studies of dual inhibitors of targets for therapy in solid tumors. We are investigating how anticancer activity is altered,
and the signal transduction paths that are activated by dual inhibitors. We are looking for students who are motivated, ambitious,
and are interested in doing research with us.

10. 劉景平 教授 Prof. Jing-Ping Liou
Medicinal Chemistry
Design and synthesis of novel small molecular compounds bearing biological functions.
Representative Publications
 Discovery and Development of small molecules in (Cancer, Neurodegenerative diseases, Thoracic
Medicine)
 Structure optimization through rational drug design approach
 Total Synthesis of natural products and its intelligent modification
1. Sharma S, Wang SA, Yang WB, Lin HY, Lai MJ, Chen HC, Kao TY, Hsu FL, Nepali K, Hsu TI*, Liou JP* First-in-class dual
EZH2-HSP90 inhibitor eliciting striking anti-glioblastoma activity in vitro and in vivo. J Med Chem. 2024 in press (IF = 7.300;
CHEMISTRY, MEDICINAL; 4/60 6.6%)
2. Sharma R, Chiang YH, Chen HC, Lin HY, Yang WB, Nepali K, Lai MJ, Chen KY, Liou JP*, Hsu, TI* Dual inhibition of
CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through
inducing DNA damage and oxidative stress. Cancer letters 2024 in press (IF = 9.700; ONCOLOGY; 34/241 14.1%)
3. Wu TY, Chen M, Chen IC, Chen YJ, Chen CY, Wang CH, Cheng JJ, Nepali K*, Chuang KH*, Liou JP*. Rational design of
synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment. J Adv Res.
2023 Apr;46:159-171. (IF = 10.700; MULTIDISCIPLINARY; 10/73 13.6%)
4. Mehndiratta S, Qian B, Chuang JY, Liou JP*, Shih JC*. N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual
Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment. J Med Chem. 2022 Feb 10;65(3):2208-
2224. (IF = 7.300; CHEMISTRY, MEDICINAL; 4/60 6.6%)
5. Ojha R, Chen IC, Hsieh CM, Nepali K, Lai RW, Hsu KC, Lin TE, Pan SL, Chen MC*, Liou JP*. Installation of Pargyline, a
LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. J
Med Chem. 2021 Dec 23;64(24):17824-17845. (IF = 7.300; CHEMISTRY, MEDICINAL; 4/60 6.6%)
Research in our laboratory is focused on the design and synthesis of small molecular compounds as anticancer. We have
experience for handling all preclinical studies toward IND, including CMC, DMPK, GLP toxicology and safety pharmacology. Dr.
Liou’s lab uses a knowledge-based drug design approach to create new and patentable small molecular compounds bearing
biological functions. Three such compounds passed US IND and are entering the human clinical trials phase.

11. 吳介信 教授 Prof. Chieh-Hsi Wu
Cardiovascular and Cancer Pharmacology
Pathological investigations and pharmacological interventions in restenosis and
cancer
Research Topics
Representative Publications
1. Zumbi CN, Pan CH, Huang HY, Wu CH*. Ascophyllum nodosum and Fucus vesiculosus ameliorate restenosis via improving
inflammation and regulating the PTEN/PI3K/AKT signalling pathway. Food Sci Hum Well. 2023, (Accepted, SCI) DOI:
10.26599/FSHW.2022.9250222
2. Tung YT, Wu CH, Chen WC, Pan CH, Chen YW, Tsao SP, Chen CJ, Huang HY*. Ascophyllum nodosum and Fucus vesiculosus
Extracts Improved Lipid Metabolism and Inflammation in High-Energy Diet–Induced Hyperlipidemia Rats. Nutrients. 2022, 14(21):
4665.
3. Pan CH, Chien YC, Sung MS, Huang HY, Sheu MJ, Wu CH*. Pathological Role of Phosphoglycerate Kinase 1 in Balloon
Angioplasty-Induced Neointima Formation. Int J Mol Sci. 2021, 22(16):8822.
4. Pan CH, Chen SY, Wang JY, Tsao SP, Huang HY, Chiu PWC, Wu CH*. Sclareol Ameliorated ERCC1-mediated Cisplatin Resistance
in A549 Human Lung Adenocarcinoma Cells and a Murine Xenograft Tumor Model by Suppressing AKT-GSK3β-AP1/Snail and JNK-
AP1 Pathways. Chem-Biol Interact. 2020, 332:109304.
 Pathological mechanisms involved in restenosis progression
 Preclinical evaluations of bioactive compounds applied for the
treatment of restenosis, hyperlipidemia, nonalcoholic fatty liver
disease (NAFLD), or non-small cell lung cancer (NSCLC)
 Drug development of drug-eluted stents
 Role and therapeutic application of gut microbiota in restenosis Differential expression proteins in
early stages of angioplasty-induced
neointimal hyperplasia.
Major research fields focus on (1) Exploration of pivotal molecules involved in
restenosis development by genomic, proteomic, or gut microbiome analyses,
which help to identify the potential therapeutic targeting molecules or disease-
specific biomarkers for clinical diagnosis. (2) Evaluation of pharmacological
activities and mechanisms of natural bioactive compounds in the prevention of
restenosis, hyperlipidemia, fatty liver, or lung cancer. (3) Developments of
candidate compounds that can help to improve the issues of side effects and
drug resistance of first-line anti-cancer drugs.
Abundance and diversity analyses
of gut microbiota after balloon
angioplasty and drug treatments.
Synergic effect of sclareol and cisplatin in a murine xenograft
tumor model.

12. 梁文俐 副教授 Associate Prof. Wen Li Liang
School of Pharmacy
Antioxidant Activity
Antibacterial Activity
Quality control of Chinese herbal medicines
Chinese herbal medicine processing
1. Yu-Chang Chen, Chia-Jung Lee, Wen-Li Liang, Shorong-Shii Liou, Chao-Lin Kuo, Ih-Sheng
Chen., Revision of the Origins and Latin Names of Crude Drugs in Taiwan Herbal Pharmacopeia
(IV), J Chin Med 32(2): 17-40, 2021.
2. Yun-Yang Lee, Hsieh-Yu Li, Shih-Jiuan Chiu, Wen-Li Liang, Pi-Li Yeh and Ying-Ling Liu (2015).
Redox reaction mediated direct synthesis of hierarchical flower-like CuO spheres anchored on
electrospun poly(vinylidene difluoride) fiber surfaces at low temperatures, The Royal Society of
Chemistry Advances, 5, 100228-100234.
3. .Lee Tzong-Huei, Tsai Yow-Fu, Huang Tzu-Tien, Chen Pi-Yu, Liang Wen-Li*, Lee Ching-Kuo*
(2012), Heptadecanols from the leaves of Persea americana var. Americana, Food Chemistry, 132,
921–924.
4. Guei-Jane Wang, Wen-Li Liang, Yu-Ming Ju, Wen-Bin Yang, Ya-Wen Chang, and Tzong-Huei
Lee (2012). Inhibitory Effects of Terpenoids from the Fermented Broth of the Ascomycete
Stilbohypoxylon elaeicola YMJ173 on Nitric Oxide Production in RAW264.7 macrophages,
Chemistry & Biodiversity(9)131-138
Representative Publications

13. 何秀娥 教授 Prof. Hsiu-O Ho
Pharmaceutical Analysis
Pharmaceutical Analysis and Drug Delivery Systems
Representative Publications
 Pharmaceutical analysis
 Application of biomaterials in drug delivery system
 Development of thermosensitive hydrogel gel
 Cancer vaccine
1. Liu YH, Chen LC, Cheng WT, Wei PS, Hsieh CM, Sheu MT, Lin SY, Ho HO* and Lin HL,* Synergistic Combination of
Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer.
Pharmaceutics 2023 January 15; 473.
2. Chou PU, Lin SY, Wu YN, Shen CY, Sheu MT*, Ho HO*, Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances
DC-targeting for cancer vaccination, Journal of Controlled Release 2022 October 351; 970.
3. Cheng WJ, Chuang KH, Lo YJ, Chen M, Chen YJ, Roffler SR, Ho HO*, Lin SY*, Sheu MT*, Bispecific T-cell Engagers Non-
covalently Decorated Drug-loaded PEGylated Nanocarriers for Cancer Immunochemotherapy, Journal of Controlled Release
2022 March 11; 344, 265-248.
4. Wei PS, Chen YJ, Lin SY, Chuang KH*, Sheu MT*, Ho HO*, In situ subcutaneously injectable thermosensitive PEG-PLGA
diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR
Fab Engager (BiTEE), Biomaterials 2021 October 5; 121166.
5. Cheng WT*, Ho HO*, Lin SY, Liu DZ, Chen LC, Sheu MT, Carfilzomib and Paclitaxel Co-Loaded Protein Nanoparticles an
Effective Therapy Against Pancreatic Adenocarcinomas. International Journal of Nanomedicine 2021 September 25; 16, 6825.
Research in our laboratory developed thermosensitive hydrogels loaded with the BiTEE and it was successfully carried out to
increase its half-life, maintain a constant blood level within therapeutic windows, and enhance T-cell recruitment to solid-tumor sites
resulting in exceptional treatment efficacy. Besides that, we also developed PLGA nanoparticles with galactose or mannose surface
decoration for co-delivery of encapsulated model antigen SIINFEKL peptide and adjuvant CpG ODN as DCs-targeting nanovaccine,
the glycosylated PLGA nanoparticles provide an effective platform to enhance the antigen presentation ability and cell immunity in
vivo that showed great potential to be developed as a prophylactic vaccine for cancer immunotherapy.

14. 何 意 副教授Associate Prof. Yih Ho
Pharmacokinetics and Pharmaceutics
The Pharmacokinetics of natural occurring compounds
 The pharmacokinetics of drugs/TCMs and their interaction
 Potential natural products having hypoglycemic activity with insulin release/glucose uptake properties.
 Pharmacophore modeling to design the potential enzyme Inhibitors (cooperated with NTUT lab)
Representative Publications
1. H. Y. Lin, Y. N. Yang, Y. F. Chen, T. Y. Huang, D. R. Crawford, H. Y. Chuang, Y. T. Chin, H. R. Chu, Z. L. Li, Y. J. Shih, Y. R. Chen, Y. S. H.
Yang, Y. Ho*, P. J. Davis, J. Whang-Peng and K. Wang: 2,3,5,4'-Tetrahydroxystilbene-2-O-beta-D-Glucoside improves female
ovarian aging. Front Cell Dev Biol, 10, 862045 (2022) doi:10.3389/fcell.2022.862045
2. S.-H. Chen, Y.-R. Wang, Y. Ho*, S.-J. LIn and H.-L. Liu: Identification of Novel CDK9 Inhibitors with Better Inhibitory Activity
and Higher Selectivity for Cancer Treatment by an Effective Two-Stage Virtual Screening Strategy. Journal of Biomedical
Science and Engineering, 14(12) (2021)
3. Y. Ho, Z. L. Li, Y. J. Shih, Y. R. Chen, K. Wang, J. Whang-Peng, H. Y. Lin and P. J. Davis: Integrin alphavbeta3 in the Mediating Effects
of Dihydrotestosterone and Resveratrol on Breast Cancer Cell Proliferation. Int J Mol Sci, 21(8) (2020)
doi:10.3390/ijms21082906
4. Y. Ho, C. Y. Wu, Y. T. Chin, Z. L. Li, Y. S. Pan, T. Y. Huang, P. Y. Su, S. Y. Lee, D. R. Crawford, K. W. Su, H. C. Chiu, Y. J. Shih,
C. A. Changou, Y. S. H. Yang, J. Whang-Peng, Y. R. Chen, H. Y. Lin, S. A. Mousa, P. J. Davis and K. Wang: NDAT suppresses
pro-inflammatory gene expression to enhance resveratrol-induced anti-proliferation in oral cancer cells. Food Chem Toxicol,
136, 111092 (2020) doi:10.1016/j.fct.2019.111092
5. J-Y Tang, Y. Ho, C-Y Chang, H-L Liu: Discovery of Novel Irreversible HER2 Inhibitors for Breast Cancer Treatment. J
Biomedical Science and Engineering 12 (4):20 (2019)
6. Y. Ho, YF Chen, LH Wang, KY Hsu,YT Chin, Y Yang, SH Wang, YR Chen, YJ Shih, LF Liu, K Wang, J Whang-Peng, HY Tang, HY Lin, HL
Liu, SJ Lin (2018) Inhibitory Effect of Anoectochilus formosanus Extract on Hyperglycemia-Related PD-L1 Expression and Cancer
Proliferation. Frontiers in Pharmacology 9:11. doi:10.3389/fphar.2018.00807
Our laboratory focus on the pharmacokinetics and mechanism of drugs. We are particularly interested in the
naturally occurring substances extracted from TCMs and some of them are consumed as dietary supplement.

15. 林淑娟 教授 Prof. Shwu-Jiuan Lin
Microbial Transformation
Medicinal Chemistry
Synthesis of natural product-like compounds to develop new bioactive substances
Microbial transformations of naturally occurring substances
The search for bioactive substances (isolation, structure elucidation, synthesis)
Research in our group is involved the isolation and structure elucidation of novel organic metabolites produced by microbial
transformation of naturally occurring substances that possess interesting structures and useful biological activities. We are also actively
collaborating with other researchers to identify and develop natural and synthetic small-molecule based candidates for antivirus,
antiinflammation and antitumor, and elucidate their corresponding mechanisms of action. The experimental approach taken by our
laboratory is multidisciplinary, relying on the tools of synthetic chemistry, medicinal chemistry, enzymology, biochemical pharmacology,
X-ray crystallography, and spectroscopy to address our goal.
Representative Publications
1. Lin, F. T., Liu. K., Wilhelms, L. A., Folly-Kossi, H., Song, Y. C., Lin, S. J., Lin, W. C. A small-molecule inhibitor of TopBP1 exerts anti-
MYC activity and synergy with PARP inhibitors. PNAS, 2023, 120, e230779312.
2. Chen, S. M., Nguyen, P. A., Burton, W., Lin, S. J., Lin, W. C., Lu, C. Y., Hsu, M. H., Cheng, C. T., Hsu, J. C. A novel prediction model
of the risk of pancreatic cancer among diabetes patients using multiple clinical data and machine learning. Cancer Med. 2023, 12,
19987-19999.
3. Liu, S. D.,† Lin, S. J.,† Ray, C. Y., Lin, F. T., Lin, W. C., Wang, L. H. Associations of warfarin use with Risks of ischemic
cerebrovascular events and major bleeding in patients with hyperthyroidism-related atrial fibrillation. Biomedicines, 2022, 10, 2152.
4. Chang, S. F., Liu, H. L., Ho, Y., Yang, L. M., Tsai, Y. E., Chou, B. H., Wang, S. H., Lin, S. J.* Transformation of 15-ene steviol by
Aspergillus niger, Cunninghamella bainieri, and Mortierella isabellina. Phytochemistry, 2021, 187, 112776.
5. Lin, S. J., Tai, L. L., Huang, Y. J., Uang, Y. S., Wang, L. H. Effect of catechin and commercial preparation of green tea essence on the
pharmacokinetics of L-dopa in rabbits. Biomed. Chromatogr. 2021, 35, e5227.
6. Ho, Y., Chen, Y. F., Wang, L. H., Hsu, K. Y., Chin, Y. T., Yang, Y. C. S. H., Wang, S. H., Chen, Y. R., Shih, Y. J., Liu, Leroy F., Wang, K.,
Whang-Peng, J., Tang, H. Y., Lin, H. Y., Liu, H. L., Lin, S. J.* Inhibitory effect of Anoectochilus formosanus Extract on hyperglycemia-
related PD-L1 expression and cancer proliferation. Frontier Pharmacol. 2018, 9, 807.
7. Kachingwe, B. H., Uang, Y. S., Huang, T. J., Wang, L. H., Lin, S. J.* Development and validation of an LC-MS/MS method
for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. J. Food Drug Anal. 2018, 26, 401−408.

16. 王莉萱 教授 Prof. Li-Hsuan Wang
Clinical pharmacokinetic, Pharmacoepidemiology and Clinical Pharmacy
and Therapeutics
 Natural product and drug interaction
 Pharmacoepidemiology and therapeutic risk management
 Medical education
 Pharmacokinetic/Pharmacodynamic study
Representative Publications
1. Wang A-Y, Lin G-L, Keller JJ, Wang L-H*. Association between antihyperlipidemic agents and the risk of
chronic periodontitis in patients with hyperlipidemia: A population-based retrospective cohort study in Taiwan.
Journal of Periodontology. 2023;1-11.(IF:4.3)
2. Lin G-L, Lin H-C, Lin H-L, Keller JJ, Wang L-H*. Association between statin use and the risk of gout in patients
with hyperlipidemia: A population-based cohort study. Frontiers in Pharmacology. 2023;14:1096999. (IF:5.6)
3. Hsu S-H, Tang K-P, Lin C-H, Chen P-C, Wang L-H*. Applying the Theory of Planned Behavior to Investigate
Type 2 Diabetes Patients’ Intention to Receive Injection Therapy. Frontiers in Public Health. 2023;11:1066633.
(IF:5.2)
4. Chen CH, Lin HC, Lin HL, Keller JJ, Wang L-H*. Association between antihyperlipidemic agent use and age-
related macular degeneration in patients with hyperlipidemia. A population-based retrospective cohort study.
Biomedicines. 2023;11:1508. (IF:4.7)
5. Cheng H-Y, Lin HC, Lin HL, Uang YS, Keller JJ, Wang L-H*. Association between nonselective beta-blocker
use and hepatocellular carcinoma in patients with chronic hepatitis B without cirrhosis and decompensation.
Frontiers in pharmacology. 2022;12:805318. (IF:5.6)
6. Liu SD, Lin SJ, Ray CY, Lin FT, Lin WC, Wang L-H*. Associations of warfarin use with risks of ischemic
cerebrovascular events and major bleeding in patients with hyperthyroidism-related atrial fibrillation.
Biomedicines. 2022;10:2670. (IF:4.7)

17. 廖嘉鴻 教授 Professor Jiahorng Liaw
Pharmaceutics
Drug and Gene Delivery with Mechanism Investigation
Research Topics
Publications:
1. HY Wang, WC Chang, MC Wu, J Liaw, AL Shiau, CY Chu. Oral DNA vaccine adjuvanted with cyclic
peptide nanotubes induced a virus-specific antibody response in ducklings against goose
parvovirus. Veterinary Quarterly 2023, 43:1-9.
2. J Liaw*, WH Hsieh, SH Chiou, US Huang, SF Chang. Assessment of the oral delivery of a myelin basic
protein gene promoter with antiapoptotic bcl-xL (pMBP-bcl-xL) DNA by cyclic peptide nanotubes with
two aspect ratios and its biodistribution in the brain and spinal cord. Mol Pharm 2021, 18: 2556-2573.
3. WH Hsieh and J Liaw*. Applications of cyclic peptide nanotubes (cPNTs). J Food Drug Anal 2019, 27:
32-47.
Patents:
1. Cyclic peptide self-assembled 3D microparticle device and manufacturing method thereof. J Liaw*, YC
Tsai, HY Wang, CSH Liaw. (2023, R.O.C., I803993).
2. Use of compounds for manufacturing medicaments for treating an autoimmune neurological disease and/pr
neurodegenerative disease. KK Huang, IH Pam, SF Wen, MN Lin, IH Lu, ZK Kuo, CH Lu, TC Lee, YY
Yang, J Liaw (2022, R.O.C., I779059).
3. Manufacturing method and use of peptide nanotube and immunogenic compositon including the same.
Wang, C Chu, AL Shiau, J Liaw, JW Lee, MC Wu (2020, R.O.C., I756948)..
4. Peptide nanotube device and manufacturing method thereof. J Liaw*, WH Hsieh, JH Chen, SF Chang,
HM Chen. (2016, R.O.C., I523667).

18. 林美香 副教授 Associate Prof. Mei-Hsiang Lin
Representative Publications
1. Chiu, P.F.; Lin, I.C.; Lu, Y.L.; Chang, C.N.; Chan, H.Y.; Lin, T.S.; Tsai, K.C.; Hsieh,Y
. S.Y.; Chen, M.J.; Lin, M. H.*; Liang, P. H.*
Design, structure–activity relationships, and enzyme kinetic studies of tricyclic and tetracyclic coumarin–based sulfamates as
steroid sulfatase inhibitors, Bioorg. Chem. 2023, 106581.
2. Kan, T.C.; Lin, M. H., Cheng, C.C.; Lu, J.W.; Sheu, M.T.; Ho, Y.S.; Sri Ra-hayu; Chang, J.S. Preclinical therapeutic assessment of
a new chemotherapeutics [dichloro(4,4'-bis(2,2,3,3-tetrafluoropropoxy)methyl)-2,2'-bi-pryridine) platinum] in an orthotopic
patient-derived xenograft 4 model of triple negative breast cancers, Pharmaceutics 2022, 14, 839.
3. Hng, Y.; Lin, M. H.; Lin, T. S.; Lu, Y
. L.; Chang, C. N.; Liu, I. C.; Tsai, K. C.; Liang, P. H.* Design and Synthesis of 3-
Benzylaminocoumarin-7-O-Sulfamate Derivatives as Steroid Sulfatase Inhibitors, Bioorg. Chem. 2020, 103618.
4. Hsu, W. J.; Lin, M. H.; Kuo, T. C.; Chou, C. M.; Mi, F. L.; Cheng, C. H.; Lin, C. W.* Fucoidan from Laminaria japonica exerts
antitumor effect on angiogenesis and micrometastasis in triple-negative breast cancer in vitro and zebrafish model in vivo, Int. J.
Biol. Macromol. 2020, 149, 600-608.
5. Mehndiratta, S.; Lin, M. H.; Wu, Y
. W.; Chen, C. H.; Wu, T. Y.; Chuang, K. H.; Chao, M. W.; Chen, Y
. Y.; Pan, S. L.; Chen, M. C.;
Liou, J. P.* N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced
PDL-1 expression, Eur. J. Med. Chem. 2020, 185, 111725.
6. Tseng, H.J.; Lin, M. H.; Shiao,Y.J.;Yang, Y.C.; Chu, J.C.; Chen, C.Y.; Chen, Y.Y.; Lin, T.E.; Su, C.J.; Pan, S.L.; Chen, L.C.; Wang,
C.Y.; Hsu, K.C.**; Huang, W.J.* Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as
multitarget agents against Alzheimer's disease, Eur. J. Med. Chem. 2020,192, 112193.
Medicinal and Organic Chemistry
Design and synthesis of novel small molecular compounds bearing biological
functions.
 Discovery and Development of small molecules
 Structure optimization through rational drug design
 Isolation and modification of natural products
Research in our laboratory is focused on the design and synthesis of small molecular compounds as anti-diabetes,
Anti-cancer Agents, and anti-inflammatory agents.

20. 王靜瓊 教授 Prof. Ching-Chiung Wang
Pharmacology of Traditional Chinese Medicine
Develop the new botanical drugs based on theory of TCM, phytochemistry
and pharmacology
Research Topics
2. Tseng SH, Lee CJ, Chen SH, Chen CH, Tsai PW, Hsieh MS, Chu JS, Wang
CC*. Cinnamic aldehyde, an anti-inflammatory component in Du-Huo-Ji-Sheng-
Tang, ameliorates arthritis in II collagenase and monosodium iodoacetate induced
osteoarthritis rat models. Journal of Traditional and Complementary Medicine.
2023,13,51-61.
3. Shiah HS, Lee CJ, Lee FY, Tseng SH, Chen SH and Wang CC*,
Chemopreventive effects of Xiang Sha Liu Jun Zi Tang on paclitaxel-induced
leucopenia and neuropathy in animals. Frontiers in Pharmacology, 2023, DOI
10.3389/fphar.2023.1106030
4. Sie YY, Chen LC, Li CJ, Yuan YH, Hsiao SH, Lee MH, Wang CC*, Hou WC*.
Inhibition of acetylcholinesterase and amyloid-β aggregation by piceatannol and
analogs: assessing in vitro and in vivo impact on a murine model of scopolamine-
induced memory impairment. Antioxidants, 2023 12 (7) 10.3390/antiox12071362
 Investigate the processed methods of TCM
 Investigate the philosophy of TCM prescription
 Investigate the pharmacology of TCM
Our research is focused on evidence-based traditional
Chinese medicines (TCM), with the aim of translating our
findings into biopharmaceutical products. First, we explore
the various processing methods applied to TCM. We
investigate the correlation between phytochemistry and
pharmacology in processed TCM, with the goal of controlling
the quality of these medicines. Second, we delve into the
philosophies behind TCM prescriptions. Since most TCM
prescriptions comprise more than four herbs, each with its
unique function, we examine the phytochemicals within these
prescriptions to discuss their clinical applications and
understand the reasons behind their compositions. Finally,
based on our findings, we aspire to create new botanical drugs
or TCM prescriptions. Our current priority is to explore the
application of TCM in treating conditions such as arthritis,
gastric ulcers, acne, osteoporosis, and chemoprevention.
Representative Publications (2020-now, 3-4
papers)
1. Lee CJ, Kapelemera AM, Tsai YZ, Lee CT, Xu MY and Wang CC*,
Evaluating the therapeutic efficacy of Si-Wu-Tang decoction and
concentrated extract in follicular maldevelopment-related menstrual
disorders through pharmacokinetic/pharmacodynamic studies. Front.
Pharmacol., 2020, 11, https://doi.org/10.3389/fphar.2020.01245

21. 李仁愛 教授 Prof. Jen-Ai Lee
Bio-Analytical Chemistry
Pharmaceutical Analysis
Representative Publications:
Discovering biomarkers of nephropathy by:
Enantiomeric separation of D,L-lactate and D,L-3-hydroxybutyrate
Differential proteomics
NMR-based metabolomics coupled with multivariate statistical analysis
1. Lin CE et al., Evaluation of the nephrotoxicity and safety of low-dose
aristolochic acid, extending to the use of Xixin (Asurum), by determination of
methylglyoxal and D-lactate. J Ethnopharmacol. 23;272:113945, 2021.
2. Hsieh CL et al., Development of a selective three-dimensional HPLC system for
enantiomer discriminated analysis of lactate and 3-hydroxybutyrate in human
plasma and urine. J Pharm Biomed Anal. 20;195:113871, 2021.
3. Chou CK et al., The Ginsenoside Rg1 Rescues Mitochondrial Disorders in
Aristolochic Acid-Induced Nephropathic Mice. Life (Basel). 27;11(10):1018,
2021.
We utilize two-dimensional HPLC coupled with fluorescence detector (FD) to
determine the concentration of D,L-lactate and D,L-3-hydroxybutyrate in kidney
damage. Our results showed that urinary D-lactate level may reflect to
nephropathy in several kidney disease models.
In differential proteomics, the proteins of kidney were derivatized with a
fluorogenic reagent DAABD-Cl and then separated by FD-LC. The differential
peaks were collected and analyzed by nanoLC-MS/MS with Mascot database
search for protein identification.
For metabolomics study, urine was analysed by nuclear magnetic resonance
(NMR)-based metabolomics coupled with multivariate statistical analysis.

22. 侯文琪 教授 Prof. Wen-Chi Hou (E-mail: wchou@tmu.edu.tw)
Functionality of natural products and proteins
Representative Publications
1. Lu, Y. L., Lin, S. Y., Fang, S. U., Hsieh, Y. Y., Chen, C. R., Wen, C. L., Chang, C. I,* Hou, W. C.* 2017. Hot-water extracts from roots of Vitis
thunbergii var. taiwaniana and identified -viniferin improve obesity in high-fat diet-induced mice. J. Agric. Food Chem. 65, 2521-2529.
2. Wu, G. C., Lin, S. Y., Liang, H. J., Hou, W. C.* 2018. 135-day interventions of yam dioscorin and the dipeptide Asn-Trp (NW) to reduce weight
gains and improve impaired glucose tolerances in high-fat diet-induced C57BL/6 mice. J. Agric. Food Chem. 66, 645-652.
3. Liu, Y. H., Lee, C. J., Chen, L. C., Lee, T. L., Hsieh, Y. Y., Han, C. H., Yang, C. H., Huang, W. J., Hou, W. C.* 2020. Acetylcholinesterase
inhibitory activity and neuroprotection in vitro, molecular docking, and improved learning and memory functions of demethylcurcumin in
scopolamine-induced amnesia ICR mice. Food and Funct. 11, 2328-2338.
4. Sie, Y. Y., Chen, L. C., Li, C. J., Yuan, Y. H., Hsiao, S. H., Lee, M. H., Wang, C. C., Hou, W. C.* 2023. Inhibition of acetylcholinesterase and
amyloid-β aggregation by piceatannol and analogues: assessing in vitro and in vivo impact on a murine model of scopolamine-induced memory
impairment. Antioxidants, 12, 1362 (https://doi.org/10.3390/antiox120713622023).
5. Liu, Y. H., Lin, Y. S., Sie, Y. Y., Wang, C. C., Chang, C. I, Hou, W. C.* 2023. Vitisin B, a resveratrol tetramer from Vitis thunbergii var. taiwaniana,
ameliorates impaired glucose regulations in nicotinamide/streptozotocin-induced type 2 diabetic mice. J. Trad. Complementary Med. 13
(https://doi.org/10.1016/j.jtcme.2023.05.003).
6. Sie, Y. Y., Chen, L. C., Li, C. W., Wang, C. C., Li, C. J., Liu, D. Z., Lee, M. H., Chen, L. G.*, Hou, W. C.*2023. Extracts and scirpusin B from
recycled seeds and rinds of passion fruits (Passiflora edulis var. Tainung No. 1) exhibit improved functions in scopolamine-induced impaired memory
ICR mice. Antioxidants 12, 2058 (https://doi.org/10.3390/antiox12122058)
Research Topics
 Antioxidant/anti-aging activity in vitro and in vivo
 Prevention against metabolic syndrome disorders
 Improved learning behavior in scopolamine-induced cognitive dysfunction mice
yam
The prevalence of dementia is increasing nearly 10 million new cases every year, and more than 55 million people are calculated to live
with dementia globally in 2023, among which Alzheimer’s disease (AD) is paid more attention because it accounts for 60% to 70% of
dementia cases in the World Health Organization reports. The pathologies of AD are characterized by synaptic failures with low levels of
acetylcholine and neuron deaths, amyloid-like fibrils via A peptide aggregations, and neurofibrillary tangles via hyper-phosphorylated
Tau protein aggregations. Several theories have been proposed with respect to the aging process, one of which is the “Free Radical Theory
of Aging.” The endogenous and environmentally induced Reactive oxygen species (ROS) in brain cells play accelerated roles in
mitochondrial dysfunction, Aβ peptide aggregation via non-enzymatic glycation, lipid peroxidation, and microglia activation linked to
impaired cognition in AD and ROS-mediated aging in the brain. Researches in my laboratory are currently focused on the
antioxidant/anti-aging/neuroprotection and preventions against metabolic syndrome disorders in vitro and in vivo by proteins, synthesized
peptides in silico, and natural products.

23. 陳世銘 教授 Prof. Shih-Ming Chen, Ph.D.
Representative Publications
1. Wang JY, Kang JW, Wu CY, Peng TR, Liao LM, Lee MC, Lee JA, Chen SM. The effects of incretin-based
therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta-
analysis. Obes Rev. 2024;10:e13686.
2. Lee MC, Peng TR, Chen BL, Lee CH, Wang JY, Lai CP, Lee JA, Chen SM, Shiang JH. Effects of various
statins on depressive symptoms: A network metaanalysis. Journal of Affective Disorders. 2021;293, 205-213.
3. Chou CK, Huang YS, Lin PY, Imai K, Chen SM, Lee JA. The Ginsenoside Rg1 Rescues Mitochondrial
Disorders in Aristolochic Acid-Induced Nephropathic Mice. Life (Basel). 2021;11(10), 1018.
4. Chen HS, Chen SM, Jiang CY, Zhang YC, Lin CY, Lin CE, Lee JA (2021, Aug). Computational tongue color
simulation in tongue diagnosis. Color Research &Application, 2021, 1–14.
Our team developed the various nephropathy mice models, including aristolochic acid
nephropathy, cisplatin-induced nephrotoxicity, and accelerated nephrotoxic serum
nephritis, to discover the natural products or other pharmaceutical drugs which could be
used for kidney diseases. Generally, our research are composed of biochemistry analysis,
histopathological examination, immunohistochemistry, and pharmacokinetic study.
Recently, we are trying to expolore the biomarkers for diagnozing kidney disease.
Clinical pharmacy and Social Pharmacy
Pharmacotherapy of Kampo Medicine
Nephrological Pharmacology
Clinical Pharmacy and Pharmacotherapy and Social Pharmacy

24. 吳姿樺 教授 Prof. Tzu‐Hua Wu, Ph.D.
Department of Clinical Pharmacy, Taipei Medical University
Biochemistry and Pharmacotherapeutics
Clinical Pharmacy & Therapeutics Drug Utilization Evaluations and Managements.
Representative Publications
 Therapeutic drug monitoring and clinical pharmacokinetics in psychiatrics and
blood disorders
 Biochemical pharmacology of Chinese herbal medicine in cataract and infertility
 Pharmaceutical care and managements
Subjects with MTHFR and PON1 Gene Polymorphisms. Nutrients 2022, 14, 3320.
Hyperprolactinemia, Metabolic Disturbance, and Sexual Dysfunction in Patients
Schizophrenia Under Olanzapine Treatment. Front Pharmacol. 2021;12:718800.
Stability and Difficulty to Treatments. Neuropsychiatr Dis Treat. 2021;17:1953-1963.
4. Syifa N, Yang JT, Wu CS, Lin MH, Wu WL, Lai CW, Ku SH, Liang SY, Hung YC, Chou CT, Wang
CS, Ishihama Y, Liao JH, Wu SH, Wu TH*. Phosphoproteomics and Bioinformatics Analyses
Reveal Key Roles of GSK-3 and AKAP4 in Mouse Sperm Capacitation. Int J Mol Sci.
2020;21(19):7283.
5. Wu CS, Chen YH, Chen CL, Chien SK, Syifa N, Hung YC, Cheng KJ, Hu SC, Lo PT, Lin SY, Wu
TH*. Constructing a bilingual website with validated database for Herb and Western
medicine interactions using Ginseng, Ginkgo and Dong Quai as examples. BMC Complement
Altern Med. 2019;19(1):335.
Dr. Wu’s researches focus on Therapeutic Drug Monitoring research particularly in the field
of Neuropsychiatry, Pediatrics and Biochemical nutrition to improve patients’ therapeutic
outcomes. Dr. Wu not only considers patients’ benefits but also put her efforts to facilitate
academic performance of pharmacists by serving as editorial member of The Journal of
Taiwan Pharmacy. She published more than 40 research articles, serves as reviewers for
several journals. Currently, Dr. Wu serves as Health Food Review Committee of the Food
and Drug Administration of the Ministry of Health and Welfare.
The study published in 2020
identified GP6 as a novel
signalling pathway by IPA
1. Lu, M.-L.; Ku, W.-C.; Syifa, N.; Hu, S.-C.; Chou, C.-T.; Wu, Y.-H.; Kuo, P.-H.; Chen, C.-H.; Chen, analysis to differentiate
W.J.; Wu, T.‐H*. Developing a Sensitive Platform to Measure 5-Methyltetrahydrofolate in phosphoproteome for sperm
capacitation 60/0 and cap
90/0datasets. Western blot
2. Wu TH, Lin CH, Goh KK, Chen CY, Chen CH, Lane HY, Lu ML. The Relationships Between analysis validated reductions
With in the protein expression of
GSK-3alpha and GSK-3beta in
capacitated sperm, and IPA
3. Hung YC, Chen HC, Kuo PH, Lu ML, Huang MC, Chen CH, Wang S, Mao WC, Wu CS, Wu TH*. upstream regulator analysis
Visualizing Patterns of Medication Switching Among Major Depressive Patients with Various predicted increased GSK-
3alpha protein activity
60/0
90/0
90/60
A sensitive and simple processing methods employing LC-MS/MS, was
successfully applied, and identified that schizophrenic patients had
significantly lower levels of 5-MTHF. Lower plasma 5-MTHF concentrations
were observed in male subjects particularly in MTHFR CT carriers.

25. 林若凱 教授 Prof. Ruo-Kai Lin
Precision Medicine
Discovery of blood biomarkers for diagnosis, prognosis and treatment.
Representative Publications
 Identification of Biomarkers Associated with Cancer and Potential Therapeutic Targets.
 Establishment of Blood Biomarkers for Early Cancer Prediction and Monitoring of Therapy Response.
1. Nguyen QTN, Nguyen PA, Wang CJ, Phuc PT, Ruo-Kai Lin, Hung CS, Kuo NH, Cheng YW, Lin SJ, Hsieh ZY, Cheng CT, Hsu
MH, Hsu JC. Machine learning approaches for predicting 5-year breast cancer survival: A multicenter study. Cancer Sci. 2023
Oct;114(10):4063-4072.
2. Ruo-Kai Lin*, Chih-Ming Su, Shih-Yun Lin, Le Thi Anh Thu, Phui-Ly Liew, Jian-Yu Chen, Huey-En Tzeng, Yun-Ru Liu, Tzu-Hao
Chang, Cheng-Yang Lee & Chin-Sheng Hung, (2022, Jan). Hypermethylation of TMEM240 predicts poor hormone therapy response
and disease progression in breast cancer. Mol Med. 28 (67).
3. Muhamad Ansar, Le Thi Anh Thu, Chin Sheng Hung, Chih Ming Su, Man Hsu Huang, Li Min Liao, Lin Ruo-Kai*. Promoter
hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer. Frontiers Oncology.
(12):1004261-1004261.
4. Yu-Han Wang, Shih-Ching Chang, Muhamad Ansar, Chin-Sheng Hung, Ruo-Kai Lin* (2021, Apr). Eps15 Homology Domain-
Containing Protein 3 Hypermethylation as a Prognostic and Predictive Marker for Colorectal Cancer. Biomedicines, 9(5):453.
5. Sheng-Chao Wang, Li-Min Liao, Muhamad Ansar, Shih-Yun Lin, Wei-Wen Hsu, Chih-Ming Su, Yu-Mei Chung, Cai-Cing Liu,
Chin-Sheng Hung, Ruo-Kai Lin* (2021, Mar). Automatic Detection of the Circulating Cell-Free Methylated DNA Pattern of
GCM2, ITPRIPL1 and CCDC181 for Detection of Early Breast Cancer and Surgical Treatment Response. Cancers. 13(6):1375.
6. Yu-Han Wang, Shih-Ching Chang, Muhamad Ansar, Chin-Sheng Hung, Ruo-Kai Lin* (2021, Apr). Eps15 Homology Domain-
Containing Protein 3 Hypermethylation as a Prognostic and Predictive Marker for Colorectal Cancer. Biomedicines, 9(5):453.
7. Shih-Ching Chang, Phui-Ly Liew, Muhamad Ansar, Shih-Yun Lin, Sheng-Chao Wang , Chin-Sheng Hung, Jian-Yu Chen, Shikha
Jain and Ruo-Kai Lin* (2020, May). Hypermethylation and Decreased Expression of TMEM240 Are Potential Early-Onset
Biomarkers for Colorectal Cancer Detection, Poor Prognosis, and Early Recurrence Prediction. Clinical epigenetics, 12(1):67.
Our laboratory specializes in discovering novel biomarkers for cancer to improve detection and treatment
monitoring. Our goal is to better patient outcomes by enabling real-time tumor tracking and early intervention,
which may prevent metastasis and foster the development of personalized medicine.

26. 莊國祥 教授 Prof. Kuo-Hsiang Chuang
Antibody/Protein Engineering, Immunotherapy, autoimmune disease
➢Bi-specific antibody-armed T cells for cancer therapy
1. ChenYJ, Chen M, ChengTL, Tsai YS, Wang CH, Chen CY, Wu TY, Tzou SC, Wang KH, Cheng JJ, KaoAP, LinSY*, Chuang KH*.
A Non-Genetic Engineering Platform for Rapidly Generating and Expanding Cancer-Specific Armed T Cells. Journal of Biomedical
Science 2023 May 31;30(1):35. IF= 11
2. Wu TY, Chen M, Chen IC, Chen YJ, Chen CY, Wang CH, Cheng JJ, Nepali K*, Chuang KH*, Liou JP*. Rational design of
synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment. Journal of
Advanced Research 2022 June 22;S2090-1232(22)00148-5. IF= 10.7
3. Cheng WJ, Chuang KH (equal 1st), Lo YJ, Chen M, Chen YJ, Roffler SR, Ho HO*, Lin SY*, Sheu MT* Bispecific T-cell engagers
non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy. Journal of Controlled Release
2022 Apr;344:235-248. IF= 10.8
4. Cheng WJ, Lin SY, Chuang KH (equal 1st), Chen M, Ho HO, Chen LC, Hsieh CM*, Sheu MT*. Combined Docetaxel/Pictilisib-
Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer.
International Journal of Nanomedicine 2022 November 17;17:5353-5374. IF= 8.0
5. Wei PS, Chen YJ, Lin SY, Chuang KH*, Sheu MT*, Ho HO*. In situ subcutaneously injectable thermosensitive PEG-PLGA
diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR
Fab Engager (BiTEE). Biomaterials 2021 October 05;278:121166. IF=14
6. Cheng WJ, Lin SY, Chen M, Chen LC , Ho HO, Chuang KH*, and Sheu MT*. Active Tumoral/Tumor Environmental Dual-Targeting by Non-
Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance
Chemotherapeutic Efficacy and Minimize Systemic Toxicity. International Journal of Nanomedicine 2021 June 10;16:4017-4030. IF= 8.0
➢Bi-specific antibody-armed nanodrugs for cancer therapy

27. 吳宗軒教授 Chung-Hsuen Wu, Professor
Research Interests: pharmacoepidemiology and outcomes research
Research Topics
Representative Publications
 Pharmacoepidemiology (藥物流行病學) and pharmacoeconomics (藥事經濟學)
 Medication adherence (服藥順從性) and health service research among patients with
chronic diseases
 Pharmaceutical outcomes research using large administrative data and complex sample
survey data (資料庫研究)
1. Huang HY, Lin SY, Katz AJ, Sheu JJ, Lin FJ, Wang CC, Wu CH.* (2022). Effectiveness and Safety of Clopidogrel versus Aspirin in
Elderly (≥80 years) with Ischemic Stroke. Mayo Clinic Proceedings, 97 (8): 1483-1492. (SCI)
2. Yang LY, Lin FJ, Katz AJ, Wang IT, Wu CH.* (2021) Prenatal Antidepressant Use and the Implication of Hypertensive Disorders
during Pregnancy. American Journal of Obstetrics and Gynecology, 225(6): 672.e1-672.e11. (SCI)
3. Hsiao SH, Hwang TJ, Lin FJ, Sheu JJ, Wu CH.* (2021). The Association between the Use of Cholinesterase Inhibitors and
Cardiovascular Events among Older Patients with Alzheimer's Disease. Mayo Clinic Proceedings, 96(2):350-362. (SCI)
Dr. Wu’s research interests focus on medication-related health outcomes, including medication adherence, persistence, and health resource
utilization among patients with chronic diseases. With multidisciplinary training in pharmacy, health policy and administration, and health
services research, Dr. Wu has extensive experience working with large health claims data and complex sample survey data to conduct
pharmaceutical outcomes research. He is familiar with administrative claims data such as MarketScan® Commercial Claims data,
MarketScan® Multi-States Medicaid Administrative data, and Humana Medicare and Commercial Claim Data as well as complex survey data
such as the Medical Expenditure Panel Survey (MEPS), National Health and Nutrition Examination Survey (NHANES), National
Comorbidity Survey-Replication (NCS-R), and National Health Interview Survey (NHIS).
Prior to his current appointment, Dr. Wu was a Human/UNC Pharmaceutical Outcomes Post-Doctoral Research Fellow in the Eshelman
School of Pharmacy at the University of North Carolina – Chapel Hill, U.S.A. He had his Bachelor of Pharmacy degree from National Taiwan
University and his Master degree in Health Policy and Administration in Washington State University U.S.A. Dr. Wu graduated from
University of Michigan U.S.A., College of Pharmacy in 2010 and had his Ph.D. degree in Clinical, Social, and Administrative Pharmacy.

28. 李學耘 教授 Prof. Hsueh‐Yun Lee
Medicinal and Organic Chemistry
Representative Publications
1. Lee, S.; Chao, M. W.; Wu, Y. W.; Hsu, C. M.; Lin, T. E.; Hsu, K. C.; Pan, S. L.; Lee, H. Y.* RSC Adv. 2023, 13,
31595- 31601.
2. Peng, C. M.; Wang, S. W.; Hwang, Y. L.; Sun, W. C.; Chiu, L. P.; Liu, Y. T.; Lai, Y. W.*; Lee, H. Y.* RSC Adv.
2023, 13, 13169-13176.
3. Lee, S. B.; Chang, T. Y.; Lee, N. Z.; , Yu, Z. Y.; Liu, C. Y.; Lee, H. Y.* Eur. J. Med. Chem. 2022, 227, 113904.
4. Lee, H. Y.; Tang, D. W.; Liu, C. Y.; Cho, E. C.* Chem. Biol. Interact. 2022, 352, 109778.
5. Cho, E. C.; Liu, C. Y.; Tang, D. W.; Lee, H. Y.* J. Enzyme Inhib. Med. Chem. 2021, 36, 1387-1401.
6. Lee, S.; Wang, S. W.; Yu, C. L.; Tai, H. C.; Yen, J. Y.; Tuan, Y. L.; Wang, H. H.; Liu, Y. T.; Chen, S. S.*; Lee, H.
Y.*
Bioorg. Med. Chem. 2021, 50, 116454.
Computer‐aided design of bioactive compounds
In silico designing novel molecules with
promising biological activity; for example,
anticancer and neurological activity.
Build‐up fragment‐based in house library
Utilizing microwave irradiator and parallel synthesis to
speed up the synthesis of a diversity of compounds for
advanced in silico screening.
Lead optimization / SAR investigation
Modifying the structure of hit/lead compounds to obtain
molecules with potent activity, which is guided by
computer modeling.
Research Topics

29. 郭俊男 助理教授 Assistant Prof. Chun-Nan Kuo
Cancer pharmacotherapy
Optimizing medication use and pharmacy service in oncology practice
Representative Publications
 Pharmacoepidemiology, pharmacovigilance and outcome research, especially in cancer treatment.
 Pharmacogenomics in cancer treatment.
 Development and evaluation of new oncology pharmacy practice model.
1. Mugiyanto E, Adikusuma W, Irham LM, Huang WC, Chang WC, Kuo CN. Integrated genomic analysis to identify druggable targets
for pancreatic cancer. Front Oncol. 2022 Dec 1;12:989077 (IF: 4.7)
2. Chang CL, Lin YJ, Pan CC, Kuo CN. Effectiveness and Safety of Lower Dose of Rivaroxaban for Cancer-Related Venous
Thromboembolism: A Retrospective Cohort Study. Ann Pharmacother. 2022 Dec;56(12):1308-1314. (IF: 2.9)
3. Chen KJ, Tai YT, Chang EH, Kuo LN, Kuo CN. Effectiveness of collaboration between oncology pharmacists and anaesthesiologists
for inpatient cancer pain management: A pilot study in Taiwan. J Int Med Res. 2021 Nov;49(11):3000605211055415 (IF: 1.6)
4. Lin YJ, Kuo CN, Ko Y. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in
Taiwan. Breast. 2021 Jun;57:18-24 (IF: 3.9)
5. Wang LC, Kuo CN, Ko Y. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in treating HER-2 positive advanced breast
cancer in Taiwan. Breast J. 2020 Oct;26(10):2099-2102 (IF: 2.1)
6. Liu YM, Kuo CN, Liou JP. Anaplastic lymphoma kinase inhibitors: an updated patent review (2014-2018). Expert Opin Ther Pat.
2020;30(5):351-373. (IF: 6.6)
7. Kuo CN, Liao YM, Kuo LN, Tsai HJ, Chang WC, Yen Y. Cancers in Taiwan: Practical insight from epidemiology, treatments,
biomarkers, and cost. J Formos Med Assoc. 2020;119(12):1731-1741 (IF: 4.0)
8. Wakabayashi G, Lee YC, Luh F, Kuo CN, Chang WC, Yen Y. Development and clinical applications of cancer immunotherapy
against PD-1 signaling pathway. J Biomed Sci. 2019;26(1):96 (IF: 11.0)
9. Kuo CN, Pan JJ, Huang YW, Tsai HJ, Chang WC. Association between Nonsteroidal Anti-Inflammatory Drugs and Colorectal
Cancer: A Population-Based Case-Control Study. Cancer Epidemiol Biomarkers Prev. 2018; 27(7): 737-45 (IF: 3.8)
Research in Dr. Kuo’s laboratory is focused on optimizing medication use and pharmacy service in oncology practice. We utilized
different approaches to achieve best medication use, including pharmacoepidemiology, pharmacovigilance, pharmacogenomics
and outcome research. We also develop and evaluate new oncology pharmacy practice model.

30. 卓爾婕 教授 Professor Er‐Chieh Cho, MSc., DPhil.
Molecular Cancer Biology and Nanomedicine
Research interests in my laboratory include molecular cancer biology in translational medicine and
biomedical applications of nanomaterials. We investigate the regulatory molecular mechanisms of tumor
development in colon cancer, and also apply various in vitro and in vivo models in other collaborative
projects such as drug development and nanocarrier development studies.
☆ Molecular regulations of oncogenes in colon cancer (癌症分子機轉探討).
☆ Cancer drug development: pre‐clinical study (新藥開發前期研究).
☆ Research of nanomaterials in biomedical applications (奈米生醫).
Selected Publications
1. Lin J, Lin JH, Yeh TY, Zheng JH, Cho EC*, Lee KC*. Fabrication of hyaluronic acid with graphene quantum dot as a dual drug
delivery system for cancer therapy. FlatChem, Volume 44, Mar 2024, 100607. p1-9.
2. Chen YL, Lee GY, Tang DW, Huang K, Lo PY, Huang JH, Cho EC*, Lee KC*. 2-Mercaptoimidazole selectively etching and thiol-
functionalized ZIF-8 metaleorganic framework to serve as a multifaceted platform for radical scavenging and Au loading.
Materials Today Chemistry. Volume 27, January 2023, 101259. p.1-12.
3. Lee HY, Tang DW, Liu CY, Cho EC*. A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell
cycle regulation. Chemico‐Biological Interactions. Volume 352, 25 January 2022, 109778. p.1-10.
4. Chen YL, Lee GY, Sung MY, Huang JH, Cho EC*, Lee KC*. Versatile Functionalization of P25 Conjugated ND Nanocomposites
for UV-Mediated Free Radical Scavenging and Facilitates Anti-Inflammation Potential in Human Cells. ACS Appl Mater
Interfaces. 2021 Aug 25;13(33):39088-39099.
5. Liu HH, Lee CH, Hsieh YC, Hsu DW, Cho EC*. Multiple myeloma driving factor WHSC1 is a transcription target of oncogene
HMGA2 that facilitates colon cancer proliferation and metastasis. Biochemical and Biophysical Research Communications
567 (2021) 183-189.
6. Cho EC, Liu CY, Tang DW and Lee HY*. Ring size changes in the development of class I HDAC inhibitors. Journal of Enzyme
Inhibition and Medicinal Chemistry. 2021, VOL. 36, NO. 1, 1387–1401.

31. Dr. Ko obtained her B.S. in Pharmacy from the National Taiwan University
and holds a Masters degree in Pharmacy Administration from the University
of Illinois at Chicago. She received her Ph.D. in Pharmaceutical Economics,
Policy, and Outcomes Research from the University of Arizona and was a
founding member of the Singapore chapter of the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR). Dr. Ko has
collaborated with local pharmacists and other health care providers on various
research projects that aim to improve the safety and cost‐ effectiveness of drug
use in Taiwan.
戈 鈺 教授 Professor Yu (Nancy) Ko, Ph.D.
Pharmacoeconomics and Outcomes Research
1. Pharmacoeconomics
3. Health service research
2. Patient-reported outcomes (PROs)
4. Psychometrics
Representative Publications
1. Hsu SW, Chiang SC, Hsu JC, Ko Y. Prescription patterns of granulocyte colony‐stimulating factors in patients with
breast cancer: A real‐world study. PLoS One. 2023;18(7):e0288642
2. Huang WC, Chen YC, Wu CH, Ko Y. Cardiovascular outcomes and healthcare costs of liraglutide versus basal
insulin for type 2 diabetes patients at high cardiovascular risk. Sci Rep. 2021;11:1430
3. Chien CL, Chen YC, Malone DC, Peng YL, Ko Y. Cost‐utility analysis of second‐line anti‐diabetic therapy in patients
with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2020;36(10):1619‐1626
4. Chou TC, Chiang SC, Ko Y. Health state utilities for metastatic breast cancer in Taiwan. Breast. 2020 Jun;51:57‐ 64.
5. Lin YJ, Wang CY, Chang EH, Cheng SW, Ko Y. Translation, revision, and validation of the Chinese version of the
Satisfaction with Oral Anti‐Diabetic Agent Scale (C‐SOADAS) in patients with type 2 diabetes mellitus. Patient
Prefer Adherence. 2018;12:667‐672

32. 李佳蓉 副教授Associate Prof. Chia‐Jung Lee, RPh, Ph.D.
Pharmacology and Pharmacokinetic Laboratory Clinical
Drug Discovery of Chinese Herbal Medicine
Bio‐assay guided fraction of TCM.
Pharmacological study of TCM, such as anti‐
inflammation, anti‐arthritis and anti‐acne effects.
Pharmacokinetics analysis of traditional Chinese
medicines by microdialysis technology and
HPLC/MS/MS analysis.
TCM‐related researches from National Health
Insurance Research Database.
Representative Publications
1. Hsieh CY, Tsai PW, Yoshihisa Tomioka, Yotaro Matsumoto, Yasutoshi Akiyama, Wang CC, Lemmuel L. Tayo,
Lee CJ.
Chronopharmacology of diuresis via metabolic profiling and key biomarker discovery of the Traditional Chinese Prescription Ji‐
Ming‐San using tandem mass spectrometry in rat models. Phytomedicine, 2023/12, 124, 155260.
2. Hsieh CY, Wang CC and Lee CJ. Identification for metabolism profiles and pharmacokinetic studies of tradition Chinese prescription
Ji‐Ming‐San and its major metabolites in rats by UHPLC‐Q‐TOF‐MS/MS and UHPLC‐MS/MS. Journal of food and drug analysis,
2023;31:502‐518
3. Alinafe Magret Kapelemera, Wang CC* and Lee CJ*, Pharmacokinetic Herb‐Drug Interactions of Xiang‐Sha‐Liu‐Jun‐Zi‐Tang and
Paclitaxel in Male Sprague Dawley Rats and Its Influence on Enzyme Kinetics in Human Liver Microsomes. Frontiers in
Pharmacology. 2022 (13):858007.
4. Lee CJ, Huang CW, Chen LG and Wang CC. (+)‐erythro‐Δ8’‐7S,8R‐ Dihydroxy‐3,3’,5’‐trimethoxy‐8‐ O‐4’‐neolignan, an anti‐acne
component in degreasing Myristica fragrans Houtt Molecules 2020/10,25, 4563.
5. Chen LW, Chung HL, Wang CC, Su JH, Chen YJ and Lee CJ. Anti‐Acne Effects of Cembrene Diterpenoids from the Cultured Soft
Coral Sinularia flexibilis Marine Drugs 2020/09, 18, 487.
6. Lee CJ, Alinafe Magret Kapelemera, Tsai TZ, Lee CZ, Xu MY and Wang CC. Evaluating the therapeutic efficacy of
Si‐Wu‐Tang
decoction and concentrated extract in follicular maldevelopment‐related menstrual disorders through
pharmacokinetic/pharmacodynamic studies. Frontiers in Pharmacology, 2020/09,11,1245
Research Topics

33. 李松柏 副教授 Associate Prof. Sung-Bau Lee
哥本哈根大學生物科技研創中心 博士後 (University of Copenhagen, Postdoc.)
中央研究院基因體研究中心 博士後 (Academia Sinica, Postdoc.)
國防醫學院生命科學研究所博士 (National Defense Medical Center, PhD)
清華大學生命科學研究所碩士 (National Tsing-Hua University, MSc)
Researches: Targeting Cell Cycle Control for Cancer Therapy
• Discover better small molecules
• Establish better strategies
Most conventional chemotherapeutics focus on the interruption of the metabolic
processes that are essential for cancer cell growth. These treatments often utilize a
relatively high dose that also interferes with normal proliferating cells, giving rise to
unwanted side effects. To resolve this problem, our laboratory is dedicating efforts to
discover potent drugs specifically targeting cancer features. We also developed
several screening platforms and SOPs to find combinational strategies that can
increase the efficacy of clinical drugs. Through collaborations with TMU chemists
and international clinical scientists, we envision that our studies will introduce
innovative approaches to reduce doses of therapeutic agents and thus spare normal
cells, providing a safer way for cancer therapy.
Representative Publications
1. TY Chang, Yan Y, NZ Lee, ……, S Gerson*, and SB Lee*. J Clin Invest, in revision. (IF: 15.9)
2. I Narwanti, ZY Yu, B Sethy……………. SB Lee*, and JP Liou*. Eur J Med Chem 2023. (IF: 6.7)
3. SB Lee, TY Change, NZ Lee ……………. HY Lee*. Eur J Med Chem 2022. (IF: 6.7)
4. TY Chang, K Nepali, YY Chen, ……, SB Lee*. Biomed Pharmacother 2021. (IF: 7.5)
5. A Singh, TY Chang, N Kaur, ……, SB Lee*, and JP Liou*. Eur J Med Chem 2021. (IF: 6.7)
6. K Nepali, TY Chang, MJ Lai, ……, SB Lee*, and JP Liou*. Eur J Med Chem 2020. (IF: 6.7)
7. SB Lee, S Segura-Bayona, M Villamor-Payà, ……, TH Stracker*, and A Groth*. Sci Adv. 2018. (IF: 13.6)

34. 王三源副教授Associate Prof. San-Yuan Wang
Bioinformatics and Omics Data Analysis
Ph.D. in Computer Science and Information Engineering, National Taiwan University
Research Topics
 Algorithm Development for MS-based Biomedical Signal Processing and Bioinformatics
 Metabolomics Data Analysis for Biomarker discovery
 Computational Chromatography and Mass Spectrometry
Milk
• Journal of Food Composition and Analysis, 2021
Irgacure-907
• Food Analytical Methods, 2022
Natural Veterinary Herbal Medicine Products
Sarcopenia
• Journal of Cachexia, Sarcopenia and Muscle, 2021
Traumatic Acid
Marker Discovery
MS-based Data Processing Pipeline
• Clinica Chimica Acta, 2023
Diagnosis of Inborn Errors of Metabolism
Our research focuses on Computational Mass Spectrometry and Bioinformatics for Metabolomics, involves the
development of new algorithms and tools for removing the background noise, normalizing and calibrating the MS
data, extracting the pure signals, quantifying and identifying the metabolites for further statistical analysis to
discover potential biomarkers for diagnosis purposes.

35. Dr. Kunal Nepali
Medicinal Chemistry
Pragmatic design of small molecule bioactive compounds
1. Design and synthesis of small molecule anticancer agents.
2. Rational design of non-purine xanthine oxidase inhibitors
3. Structural modification of phytoconstituents to amplify the bioactivity.
4. Methodology development for heterogeneous catalysis assisted multicomponent reaction.
Representative Publications
1. Sharma, S.; Chandra, K.; Naik, A.; Sharma, A.; Sharma, R.; Thakur, A.; Grewal, A.S.; Dhingra, A.K.; Banerjee, A.; Liou, J.P.; Guru,
S.K.; Nepali, K*. Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer. J Enz. Inhib. Med.
Chem. 2023, 38(1), 2276665.
2. Rana, M.; Thakur, A.; Kaur, C.; Pan, C.H.; Lee, S.B.; Liou, J.P.; Nepali, K*. Prudent tactics to sail the boat of PARP inhibitors as
therapeutics for diverse malignancies. Exp. Opin. Drug Discov. 2023, 18(10),1169-1193.
3. Sharma, R.; Chatterjee, E.; Mathew, J.; Sharma, S.; Vijayakameswara Rao, N.; Pan, C.H.; Lee, S.B.; Dhingra, A.; Grewal, A.S.;
Liou, J.P.; Guru, S.K.; Nepali, K*. Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore
culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier. Eur. J. Med. Chem. 2022, 240, 114602.
4. Thakur, A.; Faujdar, C.; Sharma, S.; Sharma, S.; Malik, B.; Nepali, K.;*Jing Ping Liou*. Glioblastoma: Current Status, Emerging
Targets, and Recent Advances. J. Med. Chem. 2022, 65, 13, 8596–8685.
5. Nepali, K.; Hsu, T.I.; Hsieh, C.M.; Lo, W.L.; Lai, M.J.; Hsu, K.C.; Lin, T.E.; Chuang, J.Y.; Liou, J.P. Pragmatic recruitment of
memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Eur. J. Med. Chem. 2021, 217, 113338.
Dr. Kunal’s research work employs a rational structure-based drug design approach that lie at the interface of
chemistry and biology. Specifically, scientific interests are inclined towards the prudent design of small molecule
inhibitors as therapeutics in cancer and gout.
CITATION METRICS
H-index -32 (SCOPUS)

36. 賴奎宏 副教授 Associate Prof. Kuei-Hung Lai
Pharmacognosy
Natural Product Chemistry, Herbal drug metabolomics
Representative Publications
 Natural products chemistry on fungi, plants, and marine organisms.
 Comparative mass spectrometry-based metabolomics strategies for
the investigation of natural products secondary metabolites.
 Illustrating the chemical defensing and communicating actions of soft
corals through analytical approaches.
 Functional and healthy food development.
1. Peng BR, Nguyen NBA, Chen LY, El-Shazly M, Hwang TL, Su JH, Lai KH*. Unprecedented anti-inflammatory
biscembranpoids with 3-hydroperoxy-3- methylcyclohex-1-ene moiety isolated from aquaculture Sarcophyton trocheliophorum.
Aquac. Rep. 2023, 33, 101835. (IF: 3.7; Rank: 16.7% in fisheries)
2. El-Sayed EK, Ibrahim RR, Ahmed AA, Khattab MA, Chen LY, Lai KH*, ElShaarawy FS, Tawfik NF, Moharram FA. Quercus
coccinea Münchh. leaves polyphenols: Appraisal acute lung injury induced by lipopolysaccharide in mice. Biomed.
Pharmacother. 2023, 164, 114765. (IF: 7.5; Rank: 8.3% in pharmacology & pharmacy)
3. Wang LS, Chen PJ, Cheng WC, Chang YC, El-Shazly M, Chen LY, Peng BR, Su CH, Yen PT, Hwang TL*, Lai KH*.
Chemometric-guided chemical marker selection: a case study of the heat-clearing herb Scrophularia ningpoensis. Front. Plant
Sci. 2023, 14, 1153710. (IF: 5.6; Rank: 11.3% in plant sciences)
4. Lai KH*, Chen YL, Lin MF, El-Shazly M, Chang YC, Chen PJ, Su CH, Chiu YC, Illias AM, Chen CC, Chen LY, Hwang TL*.
Lonicerae japonicae flos attenuates neutrophilic inflammation by inhibiting oxidative stress. Antioxidants 2022, 11, 1781. (IF: 7.0;
Rank: 8.8% in food science & technology)
5. Lai KH*, Peng BR, Hsu YM, El-Shazly M, Du YC, Lu MC, Su JH*, Liu YC*. The configuration-dependent anti-leukemic effect
of manoalide stereoisomers: reignite research interest in these sponge-derived sesterterpenoids. Bioorg. Chem. 2021, 114, 105150.
(IF: 5.1; Rank: 12.5% in organic chemistry)
6. Lai KH, Chen PJ, Chen CC, Yang SH, El-Shazly M, Chang YC, Wu YH, Wu YH, Wang YH, Hsieh HL*, Hwang TL*.
Lophatherum gracile Brongn. attenuates neutrophilic inflammation through inhibition of JNK and calcium. J. Ethnopharmacol.
2020, 264, 113224. ( IF: 5.4; Rank: 11.9% in plant sciences)

37. 謝尚逸 教授 Dr. Yves Hsieh
Bioorganic Chemistry, Biocatalysis, Glycobiology, Polysaccharide
Research Topics
Representative Publications
• Chang, S. C., Kao, M. R., Saldivar, R. K., Dí
az-Moreno, S. M., Xing, X., Furlanetto, V., Yayo, J., Divne, C., Vilaplana, F., Abbott, D. W.,
Hsieh, YSY*. The Gram-positive bacterium Romboutsia ilealis harbors a polysaccharide synthase that can produce (1,3;1,4)-β-D-
glucans. Nature Communications. 2023, 14, 4526. (IF 17)
• Hyun, G. H., Jeong, D-H., Yang, Y. Y., Cho, I. H., Ha, Y-J., Xing, X., Abbott, D. W., Hsieh, YSY, Kang, Y. P., Cha, J-H., Hong, S-S., Lee, S.
J., Kim, Y-S., Kwon, S. W.. Multivalent Carbohydrate Nanocomposites for Tumor Microenvironment Remodeling to Enhance Anti-
tumor Immunity. ACS Nano, 2023, 17, 11567−11582. (IF 17.1)
• Wang, D; Li, J; Salazar-Alvarez, G; McKee, L; Srivastava, V; Sellberg, J; Bulone, V; Hsieh, YSY*. Production of functionalised chitins
assisted by fungal lytic polysaccharide monooxygenase. Green Chem. 2018, 20, 2091-2100 (IF 9.8)
• Hsieh, YSY; Wijeyewickrema, LC, Wilkinson, BL, Pike, RN, Payne, RJ. Total synthesis of homogeneous variants of hirudin P6: A post-
translationally modified anti-thrombotic leech-derived protein. Angew. Chem. Int. Ed. 2014, 126(15): 4028-4032. (IF 16.6)
• Liao, SF; Liang, CH; Ho, MY; Hsu, TL; Tsai, TI, Hsieh, YSY, Tsai, CM; Li, ST; Cheng, YY; Tsao, SM; Lin, TY; Lin, ZY; Yang, WB; Ren, CT;
Lin, KI; Khoo, KH; Lin, CH; Hsu, HY; Wu, CY; Wong, CH. Immunization of fucose-containing polysaccharides from Reishi mushroom
induces antibodies to tumor-associated Globo H-series epitopes. PNAS. 2013, 110, (34) 13809-13814. (IF 12.0)
• Hsieh, YSY; Harris, PJ. Xyloglucans of monocotyledons have diverse structures. Mol. Plant. 2009, 2(5) 943-965. (IF 27.5)
• Chemoenzymatic synthesis of therapeutic glycoproteins and polysaccharide vaccines
• Novel enzyme technologies in pharmaceutical applications
• ​Polysaccharide sequencing in medicinal plants
Our lab is interested in the chemoenzymatic synthesis of polysaccharides,
glycoproteins and natural products, that have novel physical, chemical or
biological properties, with exciting potentials for biomaterial development
and as drug candidates for clinical applications.

38. 劉宜旻 副教授Associate Prof. Yi‐Min Liu
Medicinal Chemistry and Organic Chemistry
Research Topics
 Discovery and development of small molecules
 Structure optimization through rational drug design
 Apply organometallic coupling reaction to synthetic
route design
Research in our laboratory is focused on the design and synthesis
of small molecules as anti‐cancer, anti‐neurodegenerative, and
anti‐fibrosis agents. Our lab uses a knowledge‐based drug design
approach to create new and patentable small molecular compounds
bearing biological functions.
Representative Publications
1. Yoshihiro Oonishi, Kazuki Takagishi, Yi‐Min Liu, Yoshihiro Sato. Enantioselective Intramolecular Hydroacylation of Alkynes by
Rhodium Catalysis through Dynamic Kinetic Resolution. Advanced Synthesis & Catalysis. 2023, 365, 3432‐3437. (IF = 5.400;
CHEMISTRY, ORGANIC; 7.7%)
2. Wang YS, Yeh TK, Chang WC, Liou JP, Liu YM*, Huang WC*. 2,6‐Difluorobenzamide derivatives as store‐operated calcium
channel (SOC) inhibitors. Eur. J. Med. Chem. 2022, 243, 114773. (IF = 7.088; CHEMISTRY, MEDICINAL; 7.9%)
3. Liu YM, Tu HJ, Wu CH, Lai MJ, Yu SC, Chao MW, Wu YW, Teng CM, Pan SL*, Liou JP*. Ring‐opening of five‐membered
heterocycles conjugated 4‐isopropylresorcinol scaffold‐based benzamides as HSP90 inhibitors suppressing tumor growth in vitro
and in vivo. Eur. J. Med. Chem. 2021, 219, 113428. (IF = 7.088; CHEMISTRY, MEDICINAL; 7.9%)
4. Wu WC#, Liu YM#, Liao YH, Hsu KC, Lien ST, Chen IC, Lai MJ, Li YH, Pan SL, Chen MC*, Liou JP*.
Fluoropyrimidin‐2,4‐dihydroxy‐5‐ isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells. Eur J Med Chem.
2020, 203, 112540. (IF = 7.088; CHEMISTRY, MEDICINAL; 7.9%)
5. Wu WC#, Liu YM#, Lin MH, Liao YH, Lai MJ, Chuang HY, Hung TY, Chen CH*, Liou JP*. Design, synthesis, and evaluation of
N‐ phenyl‐4‐(2‐phenylsulfonamido)‐benzamides as microtubule‐targeting agents in drug‐resistant cancer cells, displaying HDAC
inhibitory response. Eur J Med Chem. 2020, 192, 112158. (IF = 7.088; CHEMISTRY, MEDICINAL; 7.9%)
Design and synthesis of novel small molecular compounds with biological functions

39. 吳天元 副教授 Associate Prof. Tien-Yuan Wu, Ph.D., RPh.
Pharmacovigilance
Clinical Pharmacology and Pharmacokinetics
Pharmacogenomic and Epigenomic modifications
 Pharmacovigilance and drug safety.
 Adverse drug events studies from National Health Insurance Research Database.
 Pharmacology and pharmacogenomic study of phytochemical in anti-oxidant, anti-inflammation, genomic
modification effects.
 Pharmacokinetics analysis and computational simulation of phytochemical and other compounds.
Representative Publications
1. Hsieh HH, Wu TY, Chen CH, Kuo YH, Hour MJ. Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a
retrospective cohort study. Therapeutic Advances in Drug Safety, 14:20420986231181338.
2. Wu TY, Tien N, Lin CL, Cheah YC, Hsu CY, Tsai FJ, Fang YJ, Lim YP. Influence of antipsychotic medications on hyperlipidemia risk in patients
with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression. Frontiers in Medicine,
10:1137977.
3. Hsieh HH, Wu TY, Chen CH, Kuo YH, Hour MJ. (2023, Feb). Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of
epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study. BMC Cancer, 23(1):151.
4. Alinafe Magret Kapelemera, Yow-Shieng Uang, Li-Hsuan Wang, Tien-Yuan Wu, Fang-Yu Lee, Li Tai, Ching-Chiung Wang, Chia-Jung Lee.
Pharmacokinetic Herb-Drug Interactions of Xiang-Sha-Liu-Jun-Zi-Tang and Paclitaxel in Male Sprague Dawley Rats and Its Influence on Enzyme
Kinetics in Human Liver Microsomes. Frontiers in Pharmacology, 13:858007.
5. Su YS, Kuo MZ, Kuo YT, Huang SW, Lee CJ, Su ZY, Ni YH, Li DK, Wu TY. Diterpenoid anthraquinones as chemopreventive agents altered
microRNA and transcriptome expressions in cancer cells. Biomedicine and Pharmacotherapy, 136: 111260. MOST 106-2320-B-320-003.
6. Chen CH, Hsieh HH, Wu TY. Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan. Journal of Oncology Pharmacy
Practice, 2021 Jan;27(1):63-70. doi:10.1177/1078155220913095.
7. Wu TY, Wang CH, Tien N, Lin CL, Chu FY, Chang HY, Lim YP. A Population-Based Cohort Study on the Association of Hyperthyroidism With
the Risk of Hyperlipidemia and the Effects of Anti-thyroid Drugs on Hepatic Gene Expression. Frontiers in Medicine, 2020 May 29;7:228. doi:
10.3389/fmed.2020.00228.
8. Wu TY, Lin JN, Luo ZY, Hsu CJ, Wang JS, Wu HP. 2,3,4′,5-Tetrahydroxystilbene-2-O-β-D-Glucoside (THSG) Activates the Nrf2 Antioxidant
Pathway and Attenuates Oxidative Stress-Induced Cell Death in Mouse Cochlear UB/OC-2 Cells. Biomolecules, 2020 Mar 18;10(3):465. doi:
10.3390/biom10030465.. MOST 108-2314-B-320-003.

40. 潘俊旭 專案助理教授 Project Assistant Prof. Chun-Hsu Pan
Cardiovascular and cancer pharmacology
Developments and preclinical investigations of bioactive drugs against neointimal
hyperplasia and neoplasm
Research Topics
Representative Publications
1. Zumbi CN, Pan CH, Huang HY, Wu CH*. Ascophyllum nodosum and Fucus vesiculosus ameliorate restenosis via improving
inflammation and regulating the PTEN/PI3K/AKT signalling pathway. Food Sci Hum Well. 2023, (Accepted) DOI:
10.26599/FSHW.2022.92502222.
2. Pan CH, Chien YC, Sung MS, Huang HY, Sheu MJ, Wu CH*. Pathological Role of Phosphoglycerate Kinase 1 in Balloon Angioplasty-
Induced Neointima Formation. Int J Mol Sci. 2021, 22(16):882.
3. Pan CH, Chen SY, Wang JY, Tsao SP, Huang HY, Chiu PWC, Wu CH*. Sclareol Ameliorated ERCC1-mediated Cisplatin Resistance
in A549 Human Lung Adenocarcinoma Cells and a Murine Xenograft Tumor Model by Suppressing AKT-GSK3β-AP1/Snail and JNK-
AP1 Pathways. Chem Biol Interact. 2020, 332:109304.
4. Huang WC†, Pan CH†, We CCi, Huang HY*. Lactobacillus plantarum PS128 Improves Physiological Adaptation and Performance in
Triathletes through Gut Microbiota Modulation. Nutrients. 2020, 12(8):2315.
5. Pan CH, Chen CJ, Shih CM, Wang MF, Wang JY, Wu CH*. Oxidative Stress-Induced Cellular Senescence Desensitizes Cell Growth
and Migration of Vascular Smooth Muscle Cells through Down-regulation of Platelet-Derived Growth Factor Receptor-Beta. Aging.
2019, 11(9):8085-8102.
Investigating pathological mechanisms as well as potential
predictable biomarkers and therapeutic targets in restenosis.
Screening and evaluating novel therapeutic targets and
compounds against drug resistance to chemotherapy or target
therapy in non-small cell lung cancer (NSCLC).
Our studies focused on pathological mechanisms and drug developments
of restenosis and NSCLC. Genomics and proteomics-based analysis
methods, as well as bioinformatics tools, were used to screen out the
differential expression molecules with disease-specific or cell-specific
characteristics. These candidate molecules may have the potential to be
developed as a novel therapeutic target or to be applied as a clinical
biomarker for predicting disease progression or treatment outcome.

41. 張哲邁 助理教授 Assistant Prof. Che-Mai Chang
High-Throughput Single-Cell Immunogenomic Sequencing
Single-Cell Immunogenomic Landscape in Human Diseases
Our goal is to develop advanced single-cell
immunogenomic sequencing platforms and to
identify disease-associated immunogenomic
biomarkers through in-depth single-cell analysis
for accurate diagnosis and innovative treatment
strategies.
Research Topics
Representative Publications
1. Chang CM, Chang WC, Hsieh SL. Characterization of the genetic variation and evolutionary divergence of the CLEC18
family. J Biomed Sci. 2024. 31(1):53.
2. Ho SY#, Kao CC#, Chang CM#, Chou YC, Luo WT, Chou WH, Tsai IL, Wu MS, Chang WC. Characterization of T-Cell
Receptor Repertoire in Immunoglobulin A Nephropathy. Biomark Res. 2024. 12(1):23.
3. Chang CM, Peng KY, Chan CK, Lin YF, Liao HW, Chang JG, Wu MS, Wu VC, Chang WC. Divergent Characteristics of
T-Cell Receptor Repertoire Between Essential Hypertension and Aldosterone-Producing Adenoma. Front Immunol. 2022.
13:853403.
4. Chang CM#, Feng PH#, Wu TH, Alachkar H, Lee KY, Chang WC. Profiling of T Cell Repertoire in SARS-CoV-2-
Infected COVID-19 Patients Between Mild Disease and Pneumonia. J Clin Immunol. 2021. 41(6):1131-1145.
5. Chang CM, Liao YM, Lan GY, Chang WC, Yen Y. Using T-cell repertoire profiles as predictor in a primary mucosal
melanoma. Clin Transl Med. 2020. 10(4):e136.

42. 陳宏霖 助理教授 Assistant Prof. Hung-Lin Chen
➢ Glycobiology and Immunology
➢ Galectin and Microbiota
Cell line engineering and Glycomics analysis
To investigate the role of glycosylation and galectin
in human diseases
Colon Cancer and
Microbiota Analysis
Galectin-Glycan
interaction inside cells
Representative Publications
• Chen HL, Liao F, Lin TN, and Liu FT. Galectins and
neuroinflammation. Advances in neurobiology.
2014;9:517-42.
• Chen HL, Chiang PC, Lo CH, Lo YH, Hsu DK, Chen HY, et
al. Galectin-7 Regulates Keratinocyte Proliferation and
Differentiation through JNK-miR-203-p63 Signaling. J.
Invest. Dermatol. 2016;136(1):182-91. (Impact factor:
7.143)
• H.L. Chen, C.H. Lo, C.C. Huang, M.P. Lu, P.Y. Hu, C.S.
Chen, D.Y. Chueh, P. Chen, T.N. Lin, Y.H. Lo, Y.P. Hsiao,
D.K. Hsu, F.T. Liu, (2021) Galectin-7 downregulation in
lesional keratinocytes contributes to enhanced IL-17A
signaling and skin pathology in psoriasis J Clin Invest
131, 10.1172/jci130740 (Impact factor: 14.808)
• Lo, T. H., Chen, H. L., Yao, C. I., Weng, I. C., Li, C. S.,
Huang, C. C. et al. (2021) Galectin-3 promotes
noncanonical inflammasome activation through
intracellular binding to lipopolysaccharide glycans Proc
Natl Acad Sci U S A 118, 10.1073/pnas.2026246118
(Impact factor: 11.205)
• Siew, J. J., Chen, H. M., Chiu, F. L., Lee, C. W., Chang, Y.
M., Chen, H. L. et al. (2023) Galectin-3 aggravates
microglial activation and tau transmission in tauopathy
J Clin Invest 10.1172/jci165523 (Impact factor: 19.477)
Research Topics

43. Dr. Vijayakameswara Rao. Neralla
Medicinal Polymer Chemistry
Polymer and Macromolecules synthesis for biomedical Applications
Representative Publications
1. Nanomedicine Formulation
2. Pharmaceutical Formulations
3. Pharmaceutical Polymers
4. Nano medicine
5. Stimuli responsive Polymer for drug delivery applications
1. Jacob Mathew, Trong-Nghia Le, Hoang-Phuc Pham, Pawan Kumar, Cheng-Kang Lee, Raja Shunmugam, Neralla Vijayakameswara
Rao, ROS-responsive camptothecin-linked thioketal drug delivery system based on ring-closing polymerization, European Polymer
Journal Volume 202, 5 January 2024, 112646. (IF = 5.8)
2. Hoang-Phuc Pham, Vijayakameswara Rao, N.* (2023) A hyaluronic-based prodrug with aggregation-induced emission for drug
delivery and cellular imaging, Journal of Macromolecular Science, Part A.
3. Darwin Kurniawan, Jacob Mathew, Michael Ryan Rahardja, Hoang-Phuc Pham, Pei-Chun Wong, Vijayakameswara Rao, N.*,
Kostya (Ken) Ostrikov, and Wei-Hung Chiang*. Plasma-Enabled Graphene Quantum Dot Hydrogels as Smart Anticancer Drug
Nanocarriers. Small 2023, 2206813, DOI: 10.1002/smll.202206813 (IF= 15.2)
4. Le, T.-N.; Ru, H.; Lee, C.-K*.; Vijayakameswara Rao, N.* Polynorbornene-derived block copolymer micelles via ring‐opening
metathesis polymerization with capacity of hydrogen sulfide generation. Eur Polym J 2022, 173, 111294. IF = 6.0
5. Le, T.-N.; Lin, C.-J.; Shen, Y. C.; Lin, K.-Y.; Lee, C.-K*.; Huang, C.-C.; Vijayakameswara Rao, N.* Hyaluronic Acid Derived
Hypoxia-Sensitive Nanocarrier for Tumor Targeted Drug Delivery. ACS Applied Bio Materials 2021, 4 (12), 8325-8332 IF = 4.7
6. 6) Venu, P.; Le, T. N.; Kumar, P.; Patra, D.; Kumar, R.; Lee, C. K.; Vijayakameswara Rao , N *.; Shunmugam, R*. Efficient
Design to Monitor the Site‐specific Sustained Release of a Non‐Emissive Anticancer Drug. Chemistry–An Asian Journal 2021, 16
(17), 2552-2558 IF = 4.839
The research conducted by Dr. Vijay encompasses various areas within pharmaceutical sciences and nanotechnology. His work
primarily concentrates on the development and delivery of nanomedicine, the creation of pharmaceutical formulations using
polymers, and the exploration of drug delivery systems. Dr. Vijay's expertise extends to the design of hydrogels, the advancement of
drug delivery technologies, and the development of macromolecular drugs. Additionally, his studies involve the controlled release of
large molecular drugs and the application of self-assembling nanoparticles in biomedical fields..
CITATION METRICS
H-index -23 (SCOPUS)